Braveheart Bio sets $16 IPO terms, $274.5M net proceeds, and 2029 cash runway

Filed July 30, 2026 · Compared to S-1 Jul 15, 2026 · ~2 min read

Key Changes

• high

  Offering finalized at 18.75M shares with a $16.00 assumed IPO price, targeting $274.5M net proceeds (or $316.4M if underwriters fully exercise their 2.8125M-share option).

  Use of Proceeds verify on EDGAR →
• high

  Fidelity has given a non-binding indication of interest to buy up to $75M in shares, potentially reducing public float if held long-term.

  Risk Factors verify on EDGAR →
• high

  Net proceeds plus existing cash are expected to fund operations into 2029, with $90M for obstructive HCM, $100M for non-obstructive HCM, and $135M for R&D personnel and overhead.

  Use of Proceeds verify on EDGAR →